Filter
167
Text search:
Bedaquiline
Featured
27
49
Language
Document type
106
20
19
9
5
4
2
1
1
Countries / Regions
16
14
12
4
3
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
38
31
3
2
1
Toolboxes
119
6
4
4
3
3
2
2
1
1
Interim policy guidance
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
MMWR: Recommendations and Reports / Vol. 62 / No. 9
Morbidity and Mortality Weekly Report
October 25, 2013
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
For the first time in almost 50 years there are two new drugs for the treatment of drug-resistant TB (DR-TB): bedaquiline and delamanid. There has also been increased attention given to the safety and efficacy of “re-purposed” drugs that have be
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment of TB meningitis, the use of
...
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis
...
Training for staff working at DR-TB management centres.
Training modules
